GE HealthCare agreed to acquire SOFIE Biosciences for $945 million in cash, expanding its U.S. manufacturing and distribution network for PET radiopharmaceuticals. The deal is expected to close in the first half of 2027, pending regulatory approval.

SOFIE brings 15 manufacturing sites, 21 cyclotrons and a theranostics development facility, along with U.S. rights to the Phase III FAPI-74 imaging agent. It already manufactures GE’s Flyrcado cardiac PET product.

For hospitals, the acquisition could strengthen supply reliability and access to imaging drugs. F-18’s roughly 110-minute half-life makes nearby production and timely delivery essential. Greater supplier concentration also raises contracting questions, although GE says SOFIE will continue serving existing customers and competing radiopharmaceutical providers.